| 摘要 |
A method is disclosed for the determination of 5-ASA efficacy in preventing and/or treating CRC in a mammalian, which comprises the analysis of the inhibition of the beta-catenin pathway in presence of 5-ASA. More in details, the method comprises measuring the expression of at least one gene involved in the regulation of the beta-catenin signalling pathway, such as mu-protocadherin, E-cadherin, beta-catenin, Axin1, ICAT, p21waf-1 and the expression of onco-suppressor genes, such as KLF4 and CEBPalpha. Gene expression can be measured in accordance to the methods commonly available in the art such as QRT-PCR and immunohistochemistry.
|
